Qilong Wu
24Patents
6h-index
45Co-inventors
61Inventor score
Filing activity: Dec 19, 2014 → Mar 17, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9815901B2 | Treatment of cancer using a CD123 chimeric antigen receptor | Chemistry; Metallurgy | 80 | Active |
| US9777061B2 | Treatment of cancer using a CD33 chimeric antigen receptor | Chemistry; Metallurgy | 74 | Active |
| US10174095B2 | Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor | Chemistry; Metallurgy | 27 | Active |
| US10287354B2 | Regulatable chimeric antigen receptor | Chemistry; Metallurgy | 21 | Active |
| US10640569B2 | Human mesothelin chimeric antigen receptors and uses thereof | Chemistry; Metallurgy | 8 | Active |
| US11084880B2 | Anti-BCMA chimeric antigen receptor | Chemistry; Metallurgy | 8 | Active |
| US9862760B2 | Polyomavirus neutralizing antibodies | Emerging Cross-Sectional Technologies | 6 | Active |
| US10654914B2 | Polyomavirus neutralizing antibodies | Emerging Cross-Sectional Technologies | 5 | Active |
| US10450366B2 | Polyomavirus neutralizing antibodies | Emerging Cross-Sectional Technologies | 5 | Active |
| US10435460B2 | Polyomavirus neutralizing antibodies | Emerging Cross-Sectional Technologies | 5 | Active |
| US10577417B2 | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy | Chemistry; Metallurgy | 4 | Active |
| US11161894B2 | Polyomavirus neutralizing antibodies | Emerging Cross-Sectional Technologies | 2 | Active |
| US11639378B2 | Polyomavirus neutralizing antibodies | Emerging Cross-Sectional Technologies | 1 | Active |
| US10568947B2 | Treatment of cancer using a CLL-1 chimeric antigen receptor | Chemistry; Metallurgy | 1 | Active |
| US10851166B2 | Treatment of cancer using a CD33 chimeric antigen receptor | Chemistry; Metallurgy | 1 | Active |
| US11459390B2 | Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor | Chemistry; Metallurgy | 0 | Active |
| US12214037B2 | Treatment of cancer using humanized anti-BCMA chimeric antigen receptor | Chemistry; Metallurgy | 0 | Active |
| US12077571B2 | Polyomavirus neutralizing antibodies | Emerging Cross-Sectional Technologies | 0 | Active |
| US10703819B2 | Treatment of cancer using a CD123 chimeric antigen receptor | Chemistry; Metallurgy | 0 | Active |
| US11999794B2 | Human mesothelin chimeric antigen receptors and uses thereof | Chemistry; Metallurgy | 0 | Active |
| US11591404B2 | Treatment of cancer using a CD123 chimeric antigen receptor | Chemistry; Metallurgy | 0 | Active |
| US12338287B2 | Treatment of cancer using a CD33 chimeric antigen receptor | Chemistry; Metallurgy | 0 | Active |
| US11981731B2 | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy | Chemistry; Metallurgy | 0 | Active |
| US11578130B2 | Regulatable chimeric antigen receptor | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.